Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still's disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Arthritis, Rheumatoid/*pathology ; Biomarkers/*blood ; RNA-Binding Proteins/*blood ; Still's Disease, Adult-Onset/*pathology; Adult ; Arthritis, Rheumatoid/blood ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Still's Disease, Adult-Onset/blood
    • Abstract:
      Background: Adult-onset Still's disease (AOSD) is a systemic autoinflammatory disease in which danger-associated molecular patterns (DAMPs)-mediated inflammasome activation seems to be involved in the disease pathogenesis. Cold-inducible RNA-binding protein (CIRP) belongs to a family of cold-shock proteins that respond to cellular stress and has been identified as a DAMP that triggers the inflammatory response. The aim of this study is to investigate the clinical significance of serum CIRP levels in AOSD.
      Methods: Serum samples were obtained from 44 patients with active AOSD or 50 patients with rheumatoid arthritis (RA), 20 patients with systemic lupus erythematosus (SLE), and 15 healthy control patients (HCs). Serum levels of CIRP and IL-18 were determined using enzyme-linked immunosorbent assay. Results were compared among AOSD patients, RA patients, SLE patients and HCs. Results were also analyzed according to the clinical features of AOSD.
      Results: Serum CIRP levels were significantly higher in AOSD patients compared with RA patients (median: 9.6 ng/mL, IQR [5.7-14.4] versus 3.2 ng/mL, IQR [1.9-3.8]; p < 0.001) and with HCs (2.8 ng/mL, [IQR; 1.4-4.9], p < 0.001). There was a significant positive correlation between serum CIRP levels and AOSD disease activity score (Pouchot's score r = 0.45, p = 0.003) as well as between AOSD-specific biomarkers ferritin and IL-18. However, there was no significant difference in the serum CIRP levels among AOSD patients with three different disease phenotypes.
      Conclusions: These results suggest that CIRP may play a significant role in the pathophysiology of AOSD and could be a potential biomarker for monitoring the disease activity of AOSD.
      Competing Interests: Kiyoshi Migita has received research grants from Chugai, Pfizer, and AbbVie outside the submitted work. Chugai, Pfizer, and AbbVie did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Rest of the authors declares that they have no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Gene. 1997 Dec 19;204(1-2):115-20. (PMID: 9434172)
      Sci Rep. 2016 May 24;6:26571. (PMID: 27217302)
      Clin Chim Acta. 2017 Jan;464:44-49. (PMID: 27840101)
      PLoS One. 2013;8(2):e57426. (PMID: 23437386)
      Nat Rev Rheumatol. 2018 Oct;14(10):603-618. (PMID: 30218025)
      Immune Netw. 2018 Aug 13;18(4):e27. (PMID: 30181915)
      Autoimmun Rev. 2014 Jul;13(7):708-22. (PMID: 24657513)
      Int J Rheum Dis. 2018 Jan;21(1):148-154. (PMID: 27315340)
      Nat Med. 2013 Nov;19(11):1489-1495. (PMID: 24097189)
      Front Cell Dev Biol. 2020 Aug 28;8:579157. (PMID: 32984356)
      Sci Rep. 2018 Feb 12;8(1):3052. (PMID: 29434211)
      J Leukoc Biol. 2019 Jul;106(1):133-146. (PMID: 30645013)
      Front Immunol. 2019 Oct 30;10:2536. (PMID: 31736963)
      Scand J Immunol. 2021 Jan;93(1):e12949. (PMID: 32738154)
      Rheumatology (Oxford). 2016 Dec;55(12):2237-2247. (PMID: 27616144)
      Cell Mol Life Sci. 2016 Oct;73(20):3839-59. (PMID: 27147467)
      Medicine (Baltimore). 1991 Mar;70(2):118-36. (PMID: 2005777)
      Clin Rev Allergy Immunol. 2020 Feb;58(1):71-81. (PMID: 31147820)
      Exp Cell Res. 2007 Dec 10;313(20):4130-44. (PMID: 17967451)
      J Leukoc Biol. 2019 Jul;106(1):119-125. (PMID: 30645000)
      Int J Cancer. 2017 Dec 1;141(11):2164-2173. (PMID: 28608439)
      Front Immunol. 2018 Aug 16;9:1900. (PMID: 30166988)
      J Rheumatol. 1992 Mar;19(3):424-30. (PMID: 1578458)
      J Leukoc Biol. 2020 Mar;107(3):379-391. (PMID: 31608507)
      Rheumatology (Oxford). 2020 Nov 1;59(11):3293-3302. (PMID: 32276274)
      Biochim Biophys Acta. 2010 Jan;1805(1):43-52. (PMID: 19900510)
      JCI Insight. 2020 Mar 12;5(5):. (PMID: 32027618)
      Future Sci OA. 2017 Oct 04;3(4):FSO246. (PMID: 29134130)
      Cell Mol Immunol. 2018 Jan;15(1):38-47. (PMID: 27569563)
    • Accession Number:
      0 (Biomarkers)
      0 (CIRBP protein, human)
      0 (RNA-Binding Proteins)
    • Publication Date:
      Date Created: 20210805 Date Completed: 20211129 Latest Revision: 20211129
    • Publication Date:
      20231215
    • Accession Number:
      PMC8341607
    • Accession Number:
      10.1371/journal.pone.0255493
    • Accession Number:
      34351954